1. Scrip
  2. >>Business

Lundbeck Pulled New Growth Levers In Q2

 
• By Jessica Merrill

Rexulti launch in agitation associated with Alzheimer’s disease is under way with a branded DTC marketing campaign planned for fall.

growth chart
Lundbeck turned in solid Q2 growth • Source: Shutterstock

H. Lundbeck A/S appears on solid financial footing as the company moves into a leadership transition in September. The Danish drug maker has several new growth levers to rely on as CEO Deborah Dunsire steps down on 1 September to be succeeded by Charl van Zyl, previously head of neurology at UCB S.A.. Lundbeck provided investors with a second quarter financial update on 16 August, with second quarter revenues up 10% to DKK4.94bn ($722.4m), leading the firm to slightly raise sales and earnings guidance for the year.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

In Brief: Merck To Invest $1bn In New US Biologics Production

 
• By Sushmita Panda

Merck is investing $ 1bn in a Delaware facility to produce Keytruda and expand biologics manufacturing amid US tariff concerns.

Can European Biotech Survive And Thrive In Era Of Instability?

 
• By Andrew McConaghie

Europe's biopharma sector could suffer if the Trump administration incentivizes US investment but VC leaders believe the region can still thrive and potentially capitalize on instability elsewhere.

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By Kevin Grogan

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.